Acute Myeloid Leukemia and Myelodysplastic Syndromes | Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists – Part 7: Acute Myeloid Leukemia and Myelodysplastic S

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Drs Mark Levis and David Sallman, including the following topics: Introduction Challenge of New Treatment Options for AML; Role of CPX-351 — Dr Peles Hypomethylating Agents/Venetoclax: Appropriate Candidates, Tolerability and Dose Adjustments — Dr Kumar Personal Experience with Administering Azacitidine/Venetoclax — Dr Choksi Approach to Treatment-Associated Adverse Events After the First Cycle of Venetoclax/HMA in Patients with AML Chalk Talk — Dr Sallman (Part 1) Case: A woman in her late 60s with AML — Dr Gandhi Appropriate Use of Antifungal Agents for Patients Receiving Venetoclax — Dr Apuri Role of FLT3 and IDH1/2 Inhibitors for Patients Who Are Ineligible for Intensive Induction Therapy — Dr Peles Up-Front Management of AML in Older Patients with an IDH Mutation Who Are Not Eligible for Intensive Therapy Chalk Talk — Dr Sallman (Part 2) Management of Secondary AML in Younger Patients Chalk Talk — Dr Levis (Part 1) Case: A woman in her early 80s initially treated for idiopathic thrombocytopenic purpura — Ferdy Santiago, MD Case: A woman in her late 80s with low-grade myelodysplastic syndromes with ringed sideroblasts — Dr Apuri Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Chalk Talk — Dr Levis (Part 2) CME information and select publications